Change in levels of molecules related to inflammation and immune regulation in peripheral blood of patients with lupus nephritis and their values in predicting prognosis

ZHU Honghong; MA Zhongshuang; LIU Ying

doi:10.7619/jcmp.20243153

Journal of Clinical Medicine in Practice > 2024 > 28(24): 110-115, 120. > DOI: 10.7619/jcmp.20243153

ZHU Honghong, MA Zhongshuang, LIU Ying. Change in levels of molecules related to inflammation and immune regulation in peripheral blood of patients with lupus nephritis and their values in predicting prognosis[J]. Journal of Clinical Medicine in Practice, 2024, 28(24): 110-115, 120. DOI: 10.7619/jcmp.20243153

Citation:

PDF (1728 KB)

Change in levels of molecules related to inflammation and immune regulation in peripheral blood of patients with lupus nephritis and their values in predicting prognosis

Department of Rheumatology and Immunology, Yancheng First People's Hospital in Jiangsu Province, Yancheng, Jiangsu, 224000

More Information

Received Date: July 24, 2024
Revised Date: September 22, 2024

Graphical Abstract

Abstract

Abstract

Objective
To analyze the change in levels of high mobility group box 1 protein (HMGB1), interleukin-32 (IL-32), matrix metalloproteinase-9 (MMP-9)/tissue inhibitor of metalloproteinase-1 (TIMP-1) in peripheral blood of patients with lupus nephritis (LN) and their values in predicting prognosis.
Methods
A total of 86 patients with LN from October 2021 to June 2023 were selected and treated with induction therapy for 6 months. Based on remission status of the disease, patients were divided into remission group (n=66) and non-responder group (n=20). Baseline data, change in levels and reduction rates of HMGB1, IL-32 and MMP-9/TIMP-1, and the partial correlation of reduction rates of HMGB1, IL-32 and MMP-9/TIMP-1 levels in peripheral blood with treatment response as well as their predictive values for treatment response were compared between the two groups. Disease progression was compared between patients with different reduction rates of HMGB1, IL-32 and MMP-9/TIMP-1.
Results
HMGB1, IL-32 and MMP-9/TIMP-1 levels in the remission group decreased significantly at 1 and 3 months after treatment compared to before treatment (P < 0.05); the levels of HMGB1, IL-32 and MMP-9/TIMP-1 in the remission group were significantly lower than those in the non-responder group at 1 and 3 months after treatment (P < 0.05); the reduction rates of HMGB1, IL-32 and MMP-9/TIMP-1 levels in the remission group were significantly higher than those in the non-responder group at 1 and 3 months after treatment (P < 0.05). Partial correlation analysis showed that the reduction rates of HMGB1, IL-32 and MMP-9/TIMP-1 levels were independently significantly correlated with treatment response (P < 0.05). One and three months after treatment, the values of the area under the curve (AUC) for the combined prediction of remission by the reduction rates of HMGB1, IL-32 and MMP-9/TIMP-1 levels were 0.910 and 0.932 respectively, with the AUC being the largest at 3 months after treatment (P < 0.05). Patients were divided into high and low reduction rate subgroups based on theoptimal cut-off value from the ROC curve analysis at 3 months after treatment, and the disease progression rate was significantly lower in the high reduction rate subgroup than in the low reduction rate subgroup for HMGB1, IL-32 and MMP-9/TIMP-1 (P < 0.05).
Conclusion
The great change in levels of HMGB1, IL-32 and MMP-9/TIMP-1 in peripheral blood of LN patients is significantly correlated with treatment response and disease progression, and the combined detections of HMGB1, IL-32 and MMP-9/TIMP-1 levels at 1 and 3 months after treatment have high value in predicting the treatment response of LN patients.

FullText(HTML)

References (25)

References

[1]	鲍星兰, 王丹丹, 靳子义, 等. 脐带间充质干细胞移植治疗难治性狼疮性肾炎的远期预后分析[J]. 实用临床医药杂志, 2023, 27(10): 1-5, 20. doi: 10.7619/jcmp.20230609
[2]	陈刚, 王小芳. 脂代谢紊乱与系统性红斑狼疮相关性研究[J]. 中华实用诊断与治疗杂志, 2017, 31(6): 554-555.
[3]	MOK C C, ONNO TENG Y K O, SAXENA R, et al. Treatment of lupus nephritis: consensus, evidence and perspectives[J]. Nat Rev Rheumatol, 2023, 19(4): 227-238. doi: 10.1038/s41584-023-00925-5
[4]	HISHAM F A, THARWAT S, SAMRA N E, et al. High mobility group box protein 1 (HMGB1) serum and urinary levels and gene polymorphism in Egyptian patients with systemic lupus erythematosus: a possible relation to lupus nephritis[J]. Lupus, 2022, 31(14): 1777-1785. doi: 10.1177/09612033221132484
[5]	丁昕宇, 李平, 白羽, 等. 狼疮性肾炎患者血清白细胞介素-32及肾损伤分子-1水平变化[J]. 中华实用诊断与治疗杂志, 2020, 34(1): 48-51.
[6]	唐莉, 王鹏军, 曹李娜, 等. 狼疮性肾炎患者血清中基质金属蛋白酶-9、基质金属蛋白酶抑制因子-1的表达水平及其意义[J]. 广西医学, 2018, 40(22): 2688-2691.
[7]	中国狼疮肾炎诊断和治疗指南编写组. 中国狼疮肾炎诊断和治疗指南[J]. 中华医学杂志, 2019, 99(44): 3441-3455. doi: 10.3760/cma.j.issn.0376-2491.2019.44.001
[8]	高丹, 路漫漫. 狼疮性肾炎患者临床病理特征及远期预后影响因素分析[J]. 中华实用诊断与治疗杂志, 2022, 36(1): 59-63.
[9]	张国珍, 徐志泉, 周朝艾, 等. 儿童狼疮性肾炎46例临床特点及治疗随访观察[J]. 中国医学前沿杂志: 电子版, 2018, 10(8): 26-29.
[10]	边彩月, 秦艺璐, 梁舒, 等. 血清和尿液联合检测免疫球蛋白结合蛋白1在狼疮性肾炎中的预测价值[J]. 实用临床医药杂志, 2024, 28(10): 83-86, 95. doi: 10.7619/jcmp.20233945
[11]	LAKSHMI V R, VANGALA N, UPPIN M S, et al. Revisiting vasculopathy in lupus nephritis: a renal biopsy evaluation study[J]. Indian J Nephrol, 2022, 32(1): 28-33. doi: 10.4103/ijn.IJN_131_20
[12]	LI S J, RUAN D D, WU W Z, et al. Potential regulatory role of the Nrf2/HMGB1/TLR4/NF-κB signaling pathway in lupus nephritis[J]. Pediatr Rheumatol Online J, 2023, 21(1): 130.
[13]	SHEN J, ZHANG M Y, PENG M Y. Progress of exosome research in systemic lupus erythematosus[J]. Cytokine X, 2022, 4(2/3): 100066.
[14]	ZICKERT A, PALMBLAD K, SUNDELIN B, et al. Renal expression and serum levels of high mobility group box 1 protein in lupus nephritis[J]. Arthritis Res Ther, 2012, 14(1): R36. http://www.researchgate.net/profile/Kevin_Tracey/publication/221845972_Renal_expression_and_serum_levels_of_high_mobility_group_box_1_protein_in_lupus_nephritis/links/0fcfd50868f9410944000000
[15]	张玮, 杨冉, 郭惠芳, 等. HMGB1和TNFAIP3在狼疮性肾炎系膜细胞增殖中的作用[J]. 中国药理学通报, 2017, 33(8): 1109-1113.
[16]	FENG X J, YANG R, TIAN Y X, et al. HMGB1 protein promotes glomerular mesangial matrix deposition via TLR2 in lupus nephritis[J]. J Cell Physiol, 2020, 235(6): 5111-5119. http://pubmed.ncbi.nlm.nih.gov/31667864/
[17]	ADAWY A, LI L B, HIRAO H, et al. Potential involvement of IL-32 in cell-to-cell communication between macrophages and hepatoblastoma[J]. Pediatr Surg Int, 2023, 39(1): 275.
[18]	李莉, 张老追, 李玲玲, 等. 狼疮性肾炎患者血清和尿液中IL-32和KIM-1的表达水平及临床意义[J]. 河北医药, 2019, 41(3): 361-364, 369.
[19]	BONADIO A, OGUCHE S, LAVY T, et al. Computational design of matrix metalloprotenaise-9 (MMP-9) resistant to auto-cleavage[J]. Biochem J, 2023, 480(14): 1097-1107. http://www.semanticscholar.org/paper/5a3cadaecc2338b5a1ac95f201cb406b26b8a599
[20]	ENE C D, NICOLAE I. The inflammatory profile orchestrated by inducible nitric oxide synthase in systemic lupus erythematosus[J]. J Pers Med, 2023, 13(6): 934.
[21]	HASSAN N H, YOUSEF D M, ALSEMEH A E. Hesperidin protects against aluminum-induced renal injury in rats via modulating MMP-9 and apoptosis: biochemical, histological, and ultrastructural study[J]. Environ Sci Pollut Res Int, 2023, 30(13): 36208-36227. doi: 10.1007/s11356-022-24800-0
[22]	NTRINIAS T, PAPASOTIRIOU M, BALTA L, et al. Biomarkers in progressive chronic kidney disease. still a long way to go[J]. Pril, 2019, 40(3): 27-39. http://pubmed.ncbi.nlm.nih.gov/32109222/
[23]	YAMAKOSHI S, NAKAMURA T, MORI N, et al. Effects of exercise training on renal interstitial fibrosis and renin-angiotensin system in rats with chronic renal failure[J]. J Hypertens, 2021, 39(1): 143-152. http://pubmed.ncbi.nlm.nih.gov/32833922/
[24]	BAUVOIS B, MOTHU N, NGUYEN J, et al. Specific changes in plasma concentrations of matrix metalloproteinase-2 and-9, TIMP-1 and TGF-beta1 in patients with distinct types of primary glomerulonephritis[J]. Nephrol Dial Transplant, 2007, 22(4): 1115-1122. http://europepmc.org/abstract/MED/17205957
[25]	DO VALLE G T, RICCI S T, SILVA A O, et al. Ethanol consumption increases renal dysfunction and mortality in a mice model of sub-lethal sepsis[J]. Can J Physiol Pharmacol, 2021, 99(7): 699-707. http://www.xueshufan.com/publication/3113136266

[1]	WU Di, SHEN Chunli, ZHU Jiansheng, YU Tianfu. Correlations of intelligence level and cognitive function with electroencephalogram abnormalities in children with attention deficit hyperactivity disorder[J]. Journal of Clinical Medicine in Practice, 2025, 29(1): 73-76, 93. DOI: 10.7619/jcmp.20244122
[2]	ZHANG Zhige, YU Chunlan, WEI Qi, TANG Ting, QIN Donghong, LU Lihua. Effect of hyperbaric oxygen on delayed encephalopathy after carbon monoxide poisoning and its influence on electroencephalogram[J]. Journal of Clinical Medicine in Practice, 2023, 27(8): 85-90. DOI: 10.7619/jcmp.20223568
[3]	WANG Shuyan, DU Kaixian, GUAN Jing, LI Lin, KONG Lina, DONG Yan, JIA Tianming. Features of early electroencephalogram in children with autoimmune encephalitis[J]. Journal of Clinical Medicine in Practice, 2022, 26(6): 51-53. DOI: 10.7619/jcmp.20214246
[4]	WANG Ying, LIU Min. Value of video electroencephalogram combined with neuron specific enolase detection in the diagnosis of children with febrile convulsions[J]. Journal of Clinical Medicine in Practice, 2020, 24(9): 10-12. DOI: 10.7619/jcmp.202009003
[5]	CHEN Liting, LIU Huiping, SONG Zhongrui, XU Shang, GUO Yuxiu, SHU Guihua. Clinical value of improved scoring system on amplitude integrated electroencephalogram in early prediction of neonates with bilirubin brain injury[J]. Journal of Clinical Medicine in Practice, 2020, 24(5): 21-23. DOI: 10.7619/jcmp.202005006
[6]	QIAN Youyou. Efficacy of lamotrigine combined with small dose sodium valproate in the treatment of newly diagnosed epilepsy and its influence on neurocognitive function[J]. Journal of Clinical Medicine in Practice, 2020, 24(2): 80-82. DOI: 10.7619/jcmp.202002023
[7]	MAO Yuanyuan, TENG Haiying, WANG Weihong, CHEN Shuai. Application of video electroencephalogram in evaluation of short-term prognosis in patients with acute ischemic stroke[J]. Journal of Clinical Medicine in Practice, 2019, 23(23): 5-8. DOI: 10.7619/jcmp.201923002
[9]	LU Fang. Perioperative nursing of brain tumor patients with epilepsy by electrocorticography monitoring[J]. Journal of Clinical Medicine in Practice, 2017, (8): 65-67,75. DOI: 10.7619/jcmp.201708020

Cited By

Cited by

Periodical cited type(14)

1.	李小叶，李德忠，刘叶君. 白细胞介素及胎儿纤维连接蛋白水平对早产的预测价值. 中国医师杂志. 2022(01): 101-104 .
2.	郝灿灿. 硝苯地平联合盐酸利托君治疗先兆早产的临床研究. 大医生. 2022(20): 29-31 .
3.	马依努·阿尔沙. 盐酸利托君配伍紧急宫颈环扎治疗晚期难免流产的效果. 中国继续医学教育. 2021(25): 149-153 .
4.	张红敏，宋继荣. 先兆早产患者应用盐酸利托君和硫酸镁的临床价值对比. 海峡药学. 2020(01): 146-147 .
5.	费腾. 分析不同宫缩抑制剂治疗先兆早产患者的疗效及对产妇和围生儿结局的影响. 中国医药指南. 2020(19): 52-53 .
6.	罗丽萍，童焰. 硫酸镁联合盐酸利托君在胎膜早破患者中的疗效观察及对妊娠结局的影响研究. 当代医学. 2019(30): 157-158 .
7.	冯敏. 利托君治疗胎膜早破型先兆早产的临床效果观察. 中外医学研究. 2019(30): 129-130 .
8.	张青霞，吴思懿，吴莹莹. 盐酸利托君治疗先兆早产的临床效果观察. 临床合理用药杂志. 2019(35): 82-83 .
9.	莫小跃，吴敏. 盐酸利托君与硫酸镁治疗先兆早产的效果及不良反应探讨. 中国医药科学. 2018(05): 79-81+98 .
10.	沈雪艳，张国华，张微. 乳杆菌对先兆早产患者生殖道免疫微环境的影响及意义. 山东医药. 2018(28): 83-85 .
11.	李翠丽. 盐酸利托君对于早产胎膜早破患者的临床治疗效果探究. 天津药学. 2018(03): 39-41 .
12.	亓露，齐慧丽. 盐酸利托君在妊娠期糖尿病孕妇先兆早产中的应用. 北方药学. 2018(12): 48-49 .
13.	魏然. 保胎灵胶囊辅助治疗先兆早产的可行性分析. 实用中西医结合临床. 2018(12): 135-137 .
14.	王慧娟. 硝苯地平与盐酸利托君在早产产妇中的应用效果及安全性比较. 临床医学. 2017(12): 113-114 .

Other cited types(1)

Get Citation

PDF

XML

Article views (38) PDF downloads (3) Cited by(15)

Turn off MathJax

Article Contents

Abstract

References

Change in levels of molecules related to inflammation and immune regulation in peripheral blood of patients with lupus nephritis and their values in predicting prognosis